- Product Description
- Data & Figures
- Technical Library
- Reference Literature
- Downloads
The PromoCell Cancer Cell Line Medium XF is a cell culture medium developed for the standardized in vitro cultivation of established human cancer cell lines. Its serum-free and xeno-free formulation provides a culture environment devoid of all stimuli originating from non-defined materials. Thus, it has no ill-defined components such as fetal calf serum, extracts or hydrolysates and exhibits very low lot-to-lot variability.
Components:The PromoCell Cancer Cell Line Medium XF consists of a bottle of Basal Medium and one vial of SupplementMix. Adding the SupplementMix to the Basal Medium results in the complete medium
Note: Culture vessels need to be coated. For coating we recommend using Human Fibronectin Solution (C-43060) or Vitronectin (C-69201).
Key features:
- Suitable for long-term routine culture of adherently growing established human cancer cell lines
- Compatible with most commonly used human cancer cell lines
- Xeno-free and serum-free formulation
List of cell types tested for serial passage with the PromoCell Cancer Cell Line Medium XF:
| Tissue | Tested Cell Lines | Cell Lines Origin | Remarks |
|---|---|---|---|
| Brain | BV2 | immortalized murine primary microglial cells | Coat with Fibronectin:1 µg/cm2 |
| Breast | MCF-7 | pleural effusion of metastatic human breast adenocarcinoma | Coat with Fibronectin:1 µg/cm2 |
| Colon | HT-29 | human colon adenocarcinoma | Coat with Vitronectin:0.5 µg/cm2 |
| Connective tissue | HT1080 | human fibrosarcoma | Coat with Fibronectin:1 µg/cm2 |
| Liver | HepG2 | hepatocellular carcinoma of the human liver | Coat with Vitronectin:0.5 µg/cm2 |
| Lung | A-549 | human lung carcinoma | Coat with Vitronectin:0.5 µg/cm2 |
| Prostate | LNCaP | lymph node metastasis of human prostate adenocarcinoma | 3D culture in C-28070 is recommended |
| Peripheral blood | MV-4-11 | Human acute myelogenous leukemia (suspension) | No coating required |
| Bone marrow | KG-1 | Human acute myelogenous leukemia (suspension) | No coating required |
| Kidney | ACHN | Human Renal Cell Carcinoma | Coat with Fibronectin:1 µg/cm2 |
| Brain | A172 | Human Glioblastoma | Coat with Fibronectin:1 µg/cm2 |
| Skeletal muscle | C2C12 | Mouse Myoblasts | Coat with Fibronectin:1 µg/cm2 |
| Skin | B16-F10 | Mouse Melanoma | Coat with Fibronectin:1 µg/cm2 |
| Abelson murine leukemia virus-induced tumor | RAW264.7 | Mouse Macrophage | Coat with Fibronectin:1 µg/cm2 |
| Brain, neuroectodermal | Neuro-2a | Mouse Neuroblastoma | Coat with Fibronectin:1 µg/cm2 |




ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
支原体培养则是取样后在培养基上培养,看有多少支原体菌落会长出,是比较直观和可信的结果。
总体来讲,这两种检查手段可信度都较高,结合一起,不仅可以可靠的知道有无解脲支原体感染,还能知道感染是否严重。
RMgX + RX = R-R + MgX2.
这个反应需要的能量比生成格氏试剂的高,
因此降低反应温度是第一个选择。
其次, 增加镁得摩尔比, 让 RX与镁有更多机会反应, 而不是与RMgX。
第三, 降低RX的浓度, 即用更多的溶剂, 因为溶剂和格氏试剂有很显著的溶剂络合。
第四, 缓慢滴加RX., 即降低RX.在反应体系的浓度。
第五, 增加搅拌速率, 即, 让RX.与镁有更好的接触。
ajtr0009-1230.pdf(2384.3k)
该试剂盒是一种时间分辨的荧光共振能量转移免疫分析,该反应是一个竞争免疫反应,即铕标的cAMP示踪复合物与体系中的cAMP竞争结合标有Alexa Fluor 647染料的cAMP抗体。铕标cAMP示踪复合物是通过Biotin标记的cAMP与铕标的抗生物素蛋白链菌素(streptavidin)与抗体的复合物紧密结合产生的。
当抗体结合到示踪剂上时,340nm的激发光激发铕标分子,导致能量转移到Alexa Fluor 647染料上,结果产生665nm的发射光。荧光的强度与样品中的cAMP含量成反比。
本试剂盒用于检测在GPCR激动剂刺激下活细胞或者细胞膜制备品产生的cAMP。对于偶联Gαs的受体,激动剂刺激导致665nm的荧光强度降低,而拮抗剂则可以逆转这一效应;对于偶联Gαi的受体,在激动剂刺激的同时用forskolin刺激cAMP产生,那么激动剂则抑制forskolin诱导的cAMP的生成,因此对照只给forskolin的细胞组可以通过665nm荧光强度的增加反应激动剂的效应。
该试剂盒的灵敏度很高,室温下反应在20h内是稳定的。本试剂盒适用于在384孔板中进行24μl的微量分析。

